Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106589 | 0.92 | MCHR1 (0.47) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL31106597 | 0.92 | MCHR1 (0.47) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL29956354 | 0.90 | MCHR1 (0.44) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL186606 | 0.87 | CA12 (0.43) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL9404416 | 0.81 | CA12 (0.49) | MCHR1MMP9MMP13MMP1CA12 | |
| SCHEMBL9414313 | 0.76 | MCHR1 (0.41) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL8971913 | 0.75 | MCHR1 (0.50) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL8971451 | 0.75 | MCHR1 (0.50) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL8973041 | 0.75 | MCHR1 (0.50) | MCHR1NR1I2MMP9MMP13ADAM17 | |
| SCHEMBL8970696 | 0.75 | MCHR1 (0.50) | MCHR1NR1I2MMP9MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294462-A1 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | NANOVATION THERAPEUTICS INC. (CA) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294462-A1 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | SGMS1, SGMS2, LIPC | MCHR1 4519/4885NR1I2 4171/4885MMP9 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.